PULM vs. ONCT, APRE, BIVI, APM, NNVC, LSTA, ENLV, UBX, ACST, and TXMD
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Oncternal Therapeutics (ONCT), Aprea Therapeutics (APRE), BioVie (BIVI), Aptorum Group (APM), NanoViricides (NNVC), Lisata Therapeutics (LSTA), Enlivex Therapeutics (ENLV), Unity Biotechnology (UBX), Acasti Pharma (ACST), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics (NASDAQ:ONCT) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
Pulmatrix has a net margin of -75.73% compared to Pulmatrix's net margin of -3,160.73%. Oncternal Therapeutics' return on equity of -44.05% beat Pulmatrix's return on equity.
16.1% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 3.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Pulmatrix has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.
Oncternal Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Pulmatrix received 167 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 51.85% of users gave Pulmatrix an outperform vote while only 31.18% of users gave Oncternal Therapeutics an outperform vote.
Oncternal Therapeutics presently has a consensus target price of $28.33, indicating a potential upside of 201.09%. Pulmatrix has a consensus target price of $10.00, indicating a potential upside of 446.45%. Given Oncternal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pulmatrix is more favorable than Oncternal Therapeutics.
In the previous week, Pulmatrix had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 5 mentions for Pulmatrix and 4 mentions for Oncternal Therapeutics. Pulmatrix's average media sentiment score of 0.68 beat Oncternal Therapeutics' score of 0.65 indicating that Oncternal Therapeutics is being referred to more favorably in the media.
Summary
Pulmatrix beats Oncternal Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
